Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 6;26(7):3435.
doi: 10.3390/ijms26073435.

Sidransky Syndrome- GBA1-Related Parkinson's Disease and Its Targeted Therapies

Majdolen Istaiti  1   2 , Gilad Yahalom  3 , Mikhal Cohen  3 , Volha Skrahina  1 , Aliaksandr Skrahin  1   4 , Jan Lukas  5   6 , Arndt Rolfs  1   4 , Ari Zimran  1   2
Affiliations
Review

Sidransky Syndrome- GBA1-Related Parkinson's Disease and Its Targeted Therapies

Majdolen Istaiti et al. Int J Mol Sci. .

Abstract

Sidransky syndrome represents a distinct variant of Parkinson's disease (PD) that is linked to pathogenic variants in the glucocerebrosidase (GBA1) gene. This disorder exhibits an earlier onset, a more severe course, and a higher dementia prevalence compared to idiopathic PD. While the pathogenesis remains debated between loss-of-function and gain-of-function mechanisms, targeted therapies are emerging. Pharmacological chaperones (PCs), like high-dose Ambroxol, aim to mitigate enzyme misfolding-a primary driver of this disorder-rather than addressing metabolic deficiencies seen in Gaucher disease. Despite failed trials of substrate reduction therapies, current clinical trials with Ambroxol and other PCs highlight promising avenues for disease modification. This commentary advocates for increased awareness of Sidransky syndrome to advance diagnostic strategies, promote genetic testing, and refine targeted treatments, with the potential to transform care for GBA1-related PD and prodromal stages of the disease.

Keywords: Ambroxol; GBA1-related Parkinson’s disease; Gaucher disease; Sidransky syndrome; genetic testing; pharmacological chaperones.

PubMed Disclaimer

Conflict of interest statement

M.I., A.R. and A.Z. are employees of Agyany Pharma; V.S., A.S., and J.L. are working as consultants for Agyany Pharma; the remaining authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Sidransky syndrome.
See this image and copyright information in PMC

References

    1. Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B., Zimran A. Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM. 1996;89:691–694. - PubMed
    1. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 2009;361:1651–1661. doi: 10.1056/NEJMoa0901281. - DOI - PMC - PubMed
    1. Skrahin A., Horowitz M., Istaiti M., Skrahina V., Lukas J., Yahalom G., Cohen M.E., Revel-Vilk S., Goker-Alpan O., Becker-Cohen M., et al. GBA1-Associated Parkinson’s Disease Is a Distinct Entity. Int. J. Mol. Sci. 2024;25:7102. doi: 10.3390/ijms25137102. - DOI - PMC - PubMed
    1. Horowitz M., Braunstein H., Zimran A., Revel-Vilk S., Goker-Alpan O. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Adv. Drug Deliv. Rev. 2022;187:114402. doi: 10.1016/j.addr.2022.114402. - DOI - PubMed
    1. Sardi S.P., Viel C., Clarke J., Treleaven C.M., Richards A.M., Park H., Olszewski M.A., Dodge J.C., Marshall J., Makino E., et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc. Natl. Acad. Sci. USA. 2017;114:2699–2704. doi: 10.1073/pnas.1616152114. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources